A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Megadott ok: This was a strategic business decision. There were no safety concerns contributing to this decision.
Key facts
- Where
- Cambridge, Glasgow, London és Sutton, Egyesült KirályságSee the 6 sites
- Phase
- 1/2. fázis
Where in Egyesült Királyság
- Addenbrookes HospitalCambridge, Egyesült KirályságNo longer taking part
- Beatson West of Scotland Cancer CentrewesterGlasgow, Egyesült KirályságNo longer taking part
- Guys HospitalLondon, Egyesült KirályságNo longer taking part
- St. Bartholomew's HospitalLondon, Egyesült KirályságNo longer taking part
- The Royal MarsdenLondon, Egyesült KirályságNo longer taking part
- The Royal Marsden NHS Foundation Trust - SuttonSutton, Egyesült KirályságNo longer taking part
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT05949632EU 2023-510281-27-00
- Record updated
- 2026. június 4.
- Original description
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.Read full original descriptionShow less
A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
Inclusion: Histologically confirmed advanced solid tumors (protocol-defined select solid tumors) with measurable lesions per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) that are considered non-amenable to surgery or other curative treatments or procedures; Must have disease progression on or after treatment with at least one prior systemic chemotherapy; Eastern Cooperative Oncology Group performance status score of 0 or 1; Life expectancy > 12 weeks; Willingness to avoid pregnancy.
Exclusion: Toxicity from prior therapy that has not recovered to protocol-defined limits; Prior receipt of an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; treatment with an immune modulator (eg, CTLA-4, GITR, LAG3, TIM3, OX40, ICOS, IL-2, 4-1BB, CAR-T cell); Prior therapy with antiangiogenic small-molecule TKIs targeting the VEGF pathway; Participation in another interventional clinical study while receiving INCB099280; Diagnosis of primary immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent; Received a live vaccine within 28 days of the planned start of study drug; Known additional malignancy that is progressing or requires active treatment; Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease; Impaired cardiac function or clinically significant cardiac disease; History or evidence of interstitial lung disease including noninfectious pneumonitis; Presence of gastrointestinal conditions that may affect drug absorption; Any autoimmune disease requiring systemic treatment in the past 5 years; Active infection requiring systemic therapy; History of organ transplantation, including stem cell transplantation; Laboratory values outside the Protocol-defined ranges; Receipt of systemic antibiotics within 28 days of first dose of study treatment; Probiotic usage is prohibited during screening and throughout the study treatment period; Inadequate organ function; Other protocol-defined Inclusion/Exclusion Criteria may apply.